Labelling content & Artwork management leader Kallik’s founder and CEO Neil Gleghorn has been selected as one of the 100 most influential people in the pharmaceutical sector worldwide –
Tamworth, UK August 4, 2014 –Labelling Content & Artwork Management leader Kallik is delighted to announcethat its founder and CEO Neil Gleghorn has just been recognised as one of the 100 most influential people on the global pharmaceutical stage.
The honour is confirmed by Neil being named to the landmark PharmaVOICE 100 List published by the sector’s leading independent editorial publication, PharmaVOICE.
Established nine years ago, The PharmaVOICE 100 is an annual list of individuals determined by their peers as having made the most consistent, outstanding contribution to the life sciences industry, an industry whose UK representatives generate over £50bn in sales every year according to government statistics.
According to the publishers, winners of PharmaVOICE 100 places illustrate what it means to think bigger, do more, and lead with passion and integrity, with all nominations decided by members of the sector.
“I am extremely honoured to receive this industry recognition,” said Neil.
“It is one of the most important peer awards in the pharmaceutical industry, and is testament to the work of everyone here at Kallik – not just me, but everyone from the most junior team member all the way up to the board, our partners and everyone who’s been part of the journey – and most important of all, our customers.”
A long-lasting dialogue
Neil’s extensive knowledge and understanding of the pharma industry’s specific challenges was key to his winning a PharmaVOICE 100 place. That is a knowledge base that he has used to develop forward-thinking solutions that help achieve efficiency and compliance as well as form the basis for on-going dialogues with customers about the long-term challenges they face. “What a third party like a Kallik can do is see the gaps that siloed teams in procurement, regulatory or marketing in a pharmaceutical company just can’t,” he said. “We use that perspective to develop the kind of systems that the pharmaceutical companies of today are increasingly recognising as vital in maximising their opportunity in the market.”
Kallik is a global provider of software solutions that simplify complex artwork management, generation and approval challenges for regulated industries. Its systems help such organisations to reduce the risk of product recall, guarantee product and brand consistency, mitigate risk and reduce costs.
Based on technologies using a structured data-centric approach, Kallik’s solutions leverage and repurpose content to automatically generate artwork. This enables businesses to remove duplication, track content and rapidly change messaging to respond to new market and regulatory challenges. Formed in 2001, Kallik’s founders and senior management team have a rich heritage in the packaging and labelling industry. The flagship AMS360™ Automated Artwork Management solution was devised based on this insider knowledge of the sector and today underpins the businesses of companies including Sealed Air, Estee Lauder, Coloplast, Integra, Mary Kay and Unilever.
More at www.kallik.com or follow us on Twitter @KallikAMS
About PharmaVOICE PharmaVOICE is expressly written and designed to deliver the views, opinions, and insights of executives who are shaping the direction of the dynamic life-sciences industry. PharmaVOICE, with the largest distribution in its market sector, is delivered to more than 34,000 BPA-qualified subscribers, which include executives from pharmaceutical manufacturing, biotechnology, drug discovery, research & development, contract research, drug delivery, and device/diagnostic companies. The publication also targets decision makers at healthcare advertising, marketing, medical education, public relations, information technology, contract sales, traditional and nontraditional media, and other service support companies and organizations. The publication also reaches more than 100,000 users with its digital edition, which contains original exclusive bonus content. PharmaVOICE’s unique horizontal editorial approach cuts across industry silos, providing a holistic overview of the life-sciences industry, addressing a range of topics from molecule through market. By engaging compelling personalities from diverse industry sectors, PharmaVOICE provides multiple perspectives on business challenges, trends, and topics.
More at www.pharmavoice.com